Researchers in the Department of Chemistry at Wake Forest University in collaboration with colleagues at the Wake Forest University Health Sciences Comprehensive Cancer Center have developed a new class of platinum-based anti-tumor drugs that animal studies have shown to be 10 times more effective than current treatments in destroying certain types of lung cancer cells.
The results were published in the December 11 issue of the Journal of Medicinal Chemistry and highlighted in Science-Business eXchange (SciBX), produced by Nature Publishing Group and BioCentury Publications, Inc. They suggest a new approach to fighting non-small cell lung cancer, which accounts for more than three-quarters of all lung cancers. Lung cancer is the leading cause of cancer-related deaths in both men and women. Less than a third of non-small cell lung cancer patients respond to traditional platinum-based therapies, and those who do respond have a median survival of less than a year.
“We are able to slow the growth of this cancer substantially in mice,” said principal investigator Ulrich Bierbach, Z. Smith Reynolds Foundation Fellow and associate professor of chemistry at Wake Forest. “That is very good news, since this is such a rapidly growing, intractable type of cancer.”
The new compound’s potency derives from its ability to rapidly bind with and disable a tumor cell’s DNA before the cell’s natural repair mechanisms are activated. That repair process causes drug resistance, which reduces the effectiveness of currently used platinum-based drugs.
Bierbach has focused his research efforts since 1992 on finding ways to overcome the resistance problems inherent in platinum-based drugs. He joined the Wake Forest faculty in 1999, and since 2001, has led a research team that included participation by eight graduate students and more than 30 undergraduate students. The recent paper marks the 25th he has published on the topic.
“If this ends up in clinical trials in the next few years, that will fulfill a dream of mine,” Bierbach said.
His research efforts will now be directed toward finding ways to boost the tumor-killing potency of the new compounds while reducing harmful side effects.
The new hybrid compounds are available for licensing from the Wake Forest University Office of Technology Asset Management.
- Zhidong Ma, Jayati Roy Choudhury, Marcus W. Wright, Cynthia S. Day, Gilda Saluta, Gregory L. Kucera, Ulrich Bierbach. A Non-Cross-Linking Platinum-Acridine Agent with Potent Activity in Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry, 2008; 51 (23): 7574 DOI: 10.1021/jm800900g
Cite This Page: